Cargando…

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer

The oncogenic receptor HER2 is overexpressed in many cancers, including up to 20% of breast cancers. Despite the availability of HER2-targeted treatments, patients’ disease often progresses during therapy, underscoring the need for novel treatment strategies. The addition of tucatinib, a reversible,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olson, Devra, Taylor, Janelle, Willis, Kelsi, Hensley, Kelly, Allred, Sean, Zaval, Margo, Farr, Lauren, Thurman, Robert, Jain, Nishi, Hein, Renee, Ulrich, Michelle, Peterson, Scott, Kulukian, Anita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519189/ https://www.ncbi.nlm.nih.gov/pubmed/37721518 http://dx.doi.org/10.1158/2767-9764.CRC-23-0302

Ejemplares similares

The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
por: Sirhan, Zaid, et al.
Publicado: (2022)

Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
por: Ulrich, Lara, et al.
Publicado: (2021)

Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer
por: Corti, C., et al.
Publicado: (2021)

The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2023)

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
por: Lin, Nancy U., et al.
Publicado: (2020)

53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)
por: Lin, Nancy, et al.
Publicado: (2020)

Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer
por: Cordero, Alex, et al.
Publicado: (2021)

HER2 expression and efficacy of T-DM1
por: Montemurro, Filippo
Publicado: (2014)

Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
por: Kaufman, Peter A., et al.
Publicado: (2023)

LMAP-15 INTRACRANIAL RADIOTHERAPY WITH TUCATINIB FOR BRAIN METASTASIS FROM HER2-POSITIVE BREAST CANCER: A SINGLE-INSTITUTION SERIES
por: Khatri, Vaseem, et al.
Publicado: (2023)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment
por: Topletz-Erickson, Ariel R., et al.
Publicado: (2022)

Effect of Tucatinib on Cardiac Repolarization in Healthy Volunteers
por: Topletz-Erickson, Ariel R., et al.
Publicado: (2023)

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
por: Lin, Nancy U., et al.
Publicado: (2022)

Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors
por: Sonar, Priyanka, et al.
Publicado: (2022)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
por: Bon, Giulia, et al.
Publicado: (2020)

Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer
por: Zhang, Hang, et al.
Publicado: (2017)

Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations
por: Tian, Hao, et al.
Publicado: (2023)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
por: Brand, Toni M., et al.
Publicado: (2013)

Biased activation of the receptor tyrosine kinase HER2
por: Catapano, Claudia, et al.
Publicado: (2023)

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
por: Jacot, William, et al.
Publicado: (2019)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer
por: Ma, Bo, et al.
Publicado: (2016)

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
Publicado: (2022)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
por: Nonagase, Yoshikane, et al.
Publicado: (2016)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer
por: Zhang, Jinghui, et al.
Publicado: (2021)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
por: De Giovanni, Carla, et al.
Publicado: (2021)

YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer
por: Wang, Lei, et al.
Publicado: (2020)

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
por: Mills, Matthew N., et al.
Publicado: (2021)

Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells
por: Liang, Keying, et al.
Publicado: (2021)

Correction: Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer
por: Zhang, Jinghui, et al.
Publicado: (2023)

Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers
por: Topletz-Erickson, Ariel, et al.
Publicado: (2022)

PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas
por: Aubele, M, et al.
Publicado: (2007)

HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
por: Kong, Anthony, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_96st45p1ar12tlp0esi7q3ujfi